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Background
Thiazolidinediones (troglitazone, rosiglitazone), syn-
thetic peroxisome proliferator-activated receptor agonists,
act as insulin sensitizers but beyond their antidiabetic
actions improve cardiac function in experimental ani-
mals.
Aim and methods
Our first aim was to characterise the electrophysiological
parameters of right ventricular papillary muscles from his-
tidine decarboxylase knockout (HDC KO) mice compared
with those of wild-type (WT) by standard microelectrode
technique. Furthermore we investigated the effects of ros-
iglitazone (1, 3, 30 μM) on transmembrane action poten-
tials.
Results
In KO mice statistically significant prolongation of action
potential duration (APD) and decrease in maximum rate
of rise of depolarisation phase (Vmax, dV/dt) can be
observed. Rosiglitazone caused a concentration-depend-
ent shortening of APD in both types of mice but reduced
Vmax only in WT mice.
Conclusion
The most important difference in the electrophysiological
parameters (APD, Vmax) between HDC KO and WT mice
could be due to the fact that HDC KO mice are more sus-
ceptible for hyperglycaemia. The results also suggest that
rosiglitazone might act on K+ channels and this effect
might take part in the protective effect of rosiglitazone in
ischemia/reperfusion injury observed in rats, but further,
direct ionic current measurements need to support this
explanation.
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